23rd September 2022 | Pharma Updates

Latest pharmaceutical industry news and updates

*Refresh the page if the below document does not appear.

Lupin receives approval from US FDA for generic drug

The company received the approval from US regulatory body to market the non-steroidal anti-inflammatory drug (Diclofenac Sodium Topical Solution) in the US market.The product is a generic equivalent of Horizon Pharma’s Pennsaid Topical Solution.

IOL approves investment of $2.1 Million in USpharma

The board of directors from the pharma bigshot IOL Chemicals and Pharmaceuticals Limited (IOLCP) affirmed the investment of $2.1 Million in USpharma which is an american company dealing with novel drug delivery technologies.

Kyrgyzstan invites Indian pharma investment and plans to establish special free zone

Kyrgyzstan government will be starting a special free economic zone for manufacturers specially from pharmaceutical industry. InterGovernment Committee to be set up to discuss about modalities like tax incentives.

Aster Pharmacy to open 25 stores in Bangladesh

Aster DM Healthcare announced its entry into the Bangladesh market. It aims to open 25 pharmacy stores in a span of 3 years in collaboration with GD Assist Limited, a healthcare and medical value travel management company.

Aurobindo pharma step-down subsidiary obtains EIR from US FDA

Aurolife Pharma LLC, a subsidiary of the company received an EIR (Establishment Inspection Report) from the US health authority for its plant in Raleigh, North Carolina, USA.

GSK and Spero licence agreement for tebipenem HBr

Tebipenem HBr, a late-stage antibiotic being developed by Spero, is the first oral carbapenem antibiotic that may be used to treat complicated urinary tract infections (cUTI), as per the joint announcement from GSK plc and Spero Therapeutics, Inc.

Biogen supports case for its drug under FDA review with newly published data

When a pivotal study for Biogen’s experimental ALS therapy failed to achieve its primary objective last year, the pharmaceutical company predicted that further investigation would produce more favourable outcomes.

PharmaState.academy offers easy access to training & up-skilling programs created by experts from Pharma Industry.

Update profile

Please update your profile to keep using the website

Start chat
Need Help?
PharmaState Academy
Hello, how can we help you?